Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
COVID-19
•
General Rheumatology
What are your recommendations for adjusting rheumatology medications for patients who test positive for COVID?
Is there any new data/experience since
July ACR Clinical Guidance
that has modified your practice?
Related Questions
When screening for malignancy, do you order CT with contrast (or) both with and without contrast?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Would you use febuxostat for an African-American patient with gout and previous cardiovascular events (stroke, MI) who tested positive for HLA-B*5801?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
How do you approach incidental NXP-2 antibody positivity in patients without current clinical evidence of myositis or systemic autoimmune disease?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How often do you see bony erosions in patients with Lyme arthritis?
How do you evaluate and manage brain fog in patients with underlying rheumatic disease?